Type of use | Monotherapy (N = 36) | Combination therapy (N = 6) | Total (N = 42) |
---|---|---|---|
Caspofungin first-line therapy* | 10 (28%) | 1 (17%) | 11 (26%) |
Caspofungin second-line therapy** | 26 (72%) | 5 (83%) | 31 (74%) |
Thereof reason for switching to caspofungin | |||
Clinically refractory to first-line therapy | 21 (58%) | 5 (83%) | 26 (62%) |
Toxicity with first-line therapy | 2 (6%) | 0 | 2 (5%) |
Other** | 3 (8%) | 0 | 3 (7%) |